Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions
Editat de Patrizio Lancellotti, Jose L Zamorano, Maurizio Galderisien Limba Engleză Hardback – 8 dec 2016
This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.
- Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients
- Written by world-leading experts in the field of cardiotoxicity
- Includes high-quality images, case studies, and test questions
- Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment
Preț: 641.90 lei
Preț vechi: 855.93 lei
-25% Nou
Puncte Express: 963
Preț estimativ în valută:
122.85€ • 127.61$ • 102.04£
122.85€ • 127.61$ • 102.04£
Carte tipărită la comandă
Livrare economică 27 ianuarie-10 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128025093
ISBN-10: 0128025093
Pagini: 470
Dimensiuni: 152 x 229 x 30 mm
Greutate: 0.91 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0128025093
Pagini: 470
Dimensiuni: 152 x 229 x 30 mm
Greutate: 0.91 kg
Editura: ELSEVIER SCIENCE
Cuprins
Section I: General Considerations 1. Epidemiology and Trend of Prognosis in Cancer Patients 2. Categories of Anticancer Treatments 3. Classification by Mechanisms of Cardiotoxicity 4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition? 5. The Impact of Radiotherapy
Section II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart 6. Lessons From Preclinical Models 7. Genetic and Epigenetic Risk Factors 8. Changes of Myocardial Structure and Function 9. Alteration of Heart Valves 10. Pericardial Damage 11. Effects of Radiotherapy on Vessels and Coronary Arteries 12. Cardiac Conduction Disturbances
Section III: Cardiovascular Complications of Cancer Treatments 13. Cardiac Rhythm Disturbances 14. Acute and Chronic Heart Failure 15. Coronary Artery Disease 16. Pericardial Effusion and Pericarditis 17. Radiation-Induced Carotid Atherosclerosis 18. Valvular Heart Disease 19. Atrial Fibrillation and Stroke in Cancer Patients
Section IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients 20. The Role of Echocardiography 21. The Role of Cardiovascular Magnetic Resonance (CMR) 22. Nuclear Medicine Imaging and Cardiotoxicity
Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity 23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography 24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers 25. Screening and Comprehensive Follow-Up Evaluation 26. Preoperative Assessment for Noncardiac Surgery
Section VI: Cardiotoxicity in Childhood 27. Cardiotoxicity of Childhood Cancer Treatments
Section VII: Management of Anticancer Drugs Related Cardiotoxicity 28. Nonpharmacologic Therapy 29. Beta-Blockers 30. Angiotensin-Converting Enzyme Inhibition 31. Diuretics 32. Antiarrhythmic Drugs 33. Anticoagulation in Cancer Patients 34. New Drugs: The Beneficial Effects of Ranolazine 35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients 36. Focus on the Patient With Known Cardiac Disease 37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients
Section VIII: Future Research Priorities 38. Pharmacogenomics Screening 39. Cardiac Monitoring During Clinical Trials 40. Preventive Therapy 41. Cardiotoxicity: Future Research Directions
Section II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart 6. Lessons From Preclinical Models 7. Genetic and Epigenetic Risk Factors 8. Changes of Myocardial Structure and Function 9. Alteration of Heart Valves 10. Pericardial Damage 11. Effects of Radiotherapy on Vessels and Coronary Arteries 12. Cardiac Conduction Disturbances
Section III: Cardiovascular Complications of Cancer Treatments 13. Cardiac Rhythm Disturbances 14. Acute and Chronic Heart Failure 15. Coronary Artery Disease 16. Pericardial Effusion and Pericarditis 17. Radiation-Induced Carotid Atherosclerosis 18. Valvular Heart Disease 19. Atrial Fibrillation and Stroke in Cancer Patients
Section IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients 20. The Role of Echocardiography 21. The Role of Cardiovascular Magnetic Resonance (CMR) 22. Nuclear Medicine Imaging and Cardiotoxicity
Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity 23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography 24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers 25. Screening and Comprehensive Follow-Up Evaluation 26. Preoperative Assessment for Noncardiac Surgery
Section VI: Cardiotoxicity in Childhood 27. Cardiotoxicity of Childhood Cancer Treatments
Section VII: Management of Anticancer Drugs Related Cardiotoxicity 28. Nonpharmacologic Therapy 29. Beta-Blockers 30. Angiotensin-Converting Enzyme Inhibition 31. Diuretics 32. Antiarrhythmic Drugs 33. Anticoagulation in Cancer Patients 34. New Drugs: The Beneficial Effects of Ranolazine 35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients 36. Focus on the Patient With Known Cardiac Disease 37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients
Section VIII: Future Research Priorities 38. Pharmacogenomics Screening 39. Cardiac Monitoring During Clinical Trials 40. Preventive Therapy 41. Cardiotoxicity: Future Research Directions